Pharmaceutical

Filter

Current filters:

None

Popular Filters

1 to 25 of 7207 results

European Commission approves Actavis’ Xydalba

02-03-2015

The European Commission has granted Ireland-headquartered Actavis' subsidiary Durata Therapeutics International…

ActavisAngeliniAntibiotics and Infectious diseasesDalvanceDermatologicalsDurata TherapeuticsEuropePharmaceuticalXydalba

GSK and Novartis complete major three-part transaction

02-03-2015

UK pharma major GlaxoSmithKline said this morning that its three-part transaction with Swiss peer Novartis…

GlaxoSmithKlineMergers & AcquisitionsNovartisOncologyPharmaceuticalVaccines

China regulates hospital drug purchasing

02-03-2015

A document on hospital drug purchasing in China was released Saturday, which instructed that hospitals…

ChinaFinancialHealthcarePharmaceutical

Taiho Pharma Europe submits marketing application to EMA for TAS-102 in colorectal cancer

Taiho Pharma Europe submits marketing application to EMA for TAS-102 in colorectal cancer

02-03-2015

Taiho Pharma Europe, a subsidiary of Japanese pharma company Otsuka (TYO: 4768), has submitted a marketing…

EuropeOncologyPharmaceuticalRegulationTaiho PharmaceuticalsTAS-102

Global drugmakers slam restrictions on state tendering in Russia

02-03-2015

Leading global pharmaceutical producers operating in the Russian market have criticized a recent decision…

PharmaceuticalPricingRegulationRussia

South Korea pharma news briefs

02-03-2015

News items, as posted by the Korean Research-based Pharmaceutical Industry Association (KRPIA) last month,…

FinancialPharmaceuticalPricingRegulationSouth Korea

Novartis hit with 15-day suspension over omission of adverse events reporting

Novartis hit with 15-day suspension over omission of adverse events reporting

02-03-2015

Swiss drug major Novartis has been ordered to suspend operations in Japan for 15 days as of March 5,…

JapanLegalNovartisPharmaceuticalRegulation

AstraZeneca to spin-out early-stage antibiotic R&D into stand-alone company

AstraZeneca to spin-out early-stage antibiotic R&D into stand-alone company

28-02-2015

Anglo-Swedish pharma major AstraZeneca is changing the structure of its small-molecule early-stage anti-infectives…

Antibiotics and Infectious diseasesAstraZenecaMergers & AcquisitionsPharmaceuticalResearchUK

Three new drugs recommended for approval by EMA/CHMP

Three new drugs recommended for approval by EMA/CHMP

27-02-2015

Three new medicines have been recommended for approval at the February 2015 meeting of the European Medicines…

AmgenEuropeJinarcNephrology and HepatologyNovartisOncologyOtsuka PharmaceuticalPharmaceuticalRegulationRistempaVectibixZykadia

UCB's full-year results

UCB's full-year results "confirm position of strength"

27-02-2015

The 2014 full-year financial results from Belgian drugmaker UCB “confirmed the position of strength”…

BelgiumCimziaFinancialImmunologicalsKeppraNeuproNeurologicalPharmaceuticalUCBVimpat

India plans to impose price controls on medical device makers and distributors

India plans to impose price controls on medical device makers and distributors

27-02-2015

In a major crackdown, India's drug regulator the National Pharmaceutical Pricing Authority has come down…

IndiaPharmaceuticalPricingRegulation

PHARMAC in negotiations over rare disorders medicines

PHARMAC in negotiations over rare disorders medicines

27-02-2015

New Zealand’s Pharmaceutical Management Agency, PHARMAC, is in active negotiations with several suppliers…

FinancialHealthcareNew ZealandPharmaceuticalPricingRare diseases

Former Sanofi chief Christopher Viehbacher joins PureTech

Former Sanofi chief Christopher Viehbacher joins PureTech

27-02-2015

The former chief executive of French pharma major Sanofi Christopher Viehbacher has been appointed to…

BoardroomChristopher ViehbacherPharmaceuticalSanofi

EC approves Zambon and Newron’s Xadago for late-stage PD patients

EC approves Zambon and Newron’s Xadago for late-stage PD patients

27-02-2015

Zambon and its partner, fellow Italy-based Newron Pharmaceuticals, have received approval from the European…

EuropeNeurologicalNewron PharmaceuticalsPharmaceuticalRegulationXadagoZambon

Amgen and Onyx’s MAA for Kyprolis is accepted by EMA

Amgen and Onyx’s MAA for Kyprolis is accepted by EMA

27-02-2015

The European Medicines Agency has accepted the Marketing Authorization Application for Kyprolis (carfilzomib)…

AmgenEuropeKyprolisOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

BIA welcomes UK’s R&D tax credit scheme

BIA welcomes UK’s R&D tax credit scheme

27-02-2015

The UK BioIndustry Association (BIA) is calling for an extended advance assurance scheme in its response…

FinancialPharmaceuticalUKUK BioIndustry AssociationUnited Kingdom

Chiesi found to have breached ABPI Code

Chiesi found to have breached ABPI Code

27-02-2015

Privately-held Italian drugmaker Chiesi Farmaceutici has been publicly reprimanded for providing inaccurate…

Chiesi FarmaceuticiFostairLegalPharmaceuticalRegulationUK

2015 outlook for US and EU pharma; report

2015 outlook for US and EU pharma; report

27-02-2015

According to this Global Pharma US & EU Outlook 2015 report, strategy diversification stays divested…

EuropeManagementMarkets & MarketingMergers & AcquisitionsPatentsPharmaceuticalUSA

2014 a record year for Bayer, with pharma fired up by new products

2014 a record year for Bayer, with pharma fired up by new products

27-02-2015

For German pharma major Bayer, 2014 proved to be a record year, with the company notching up sales of…

BayerFinancialGermanyManagementMarijn DekkersPharmaceutical

Report: Japanese pharma market edging towards $80 Billion by 2020

Report: Japanese pharma market edging towards $80 Billion by 2020

26-02-2015

Japan’s pharmaceutical market value is set to grow at a tepid Compound Annual Growth Rate (CAGR) of…

Bristol-Myers SquibbGlobalDataJapanMarkets & MarketingPharmaceutical

Mundipharma launches monoclonal antibody Remsima in six European markets

26-02-2015

Privately-held UK-based drugmaker Mundipharma International is launching Remsima (infliximab) this month…

Anti-Arthritics/RheumaticsEuropeMarkets & MarketingMundipharmaPharmaceuticalRemsima

Significant drop in pharma applications to EPO shows pace of innovation is dropping

Significant drop in pharma applications to EPO shows pace of innovation is dropping

26-02-2015

The European Patent Office (EPO) has reported an increase in the number of patent filings for the fifth…

BiotechnologyEPOEuropeLegalPharmaceutical

Economist Pharma Summit: BRIC countries must be at forefront of AMR fight, says Jim O'Neill

Economist Pharma Summit: BRIC countries must be at forefront of AMR fight, says Jim O'Neill

26-02-2015

Jim O'Neill, chair of the UK government's review on antimicrobial resistance (AMR), spoke of the need…

AMRAntibiotics and Infectious diseasesPharma SummitPharmaceuticalUK

Ablynx 2014 financial results sees loss decrease thanks to collaborations

Ablynx 2014 financial results sees loss decrease thanks to collaborations

26-02-2015

Belgian drug developer Ablynx has released its 2014 full year results, reporting a decreased loss from…

AblynxBelgiumFinancialMerck & CoPharmaceutical

1 to 25 of 7207 results

COMPANY SPOTLIGHT

Menarini

Back to top